eCoin
Commercial- Indications
- Urge urinary incontinence
Company intelligence / Profile preview
The eCoin® system, an implantable tibial nerve stimulator, received FDA approval in March 2022 and has demonstrated that at one year post-procedure, at least a 50% reduction in UUI episodes was achieved by approximately 75% of patients. The device offers minimally invasive implantation with no need for recharging or patient programming. Early-stage trials are ongoing for additional indications such as hypertension.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Valencia Technologies.